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There is strong association of Alzheimer’s disease (AD) pathology with gait disorder and
falls in older adults without dementia. The goal of the study was to examine the prevalence
and severity of AD pathology in older adults without dementia who fall and sustain hip
fracture.
Methods
Cerebrospinal fluid (CSF) was obtained from 168 hip fracture patients. CSF Aβ42/40 ratio,
p-tau, and t-tau measures were dichotomized into normal vs. abnormal, and categorized
according to the A/T/N classification.
Results
Among the hip fracture patients, 88.6% of the cognitively normal (Clinical Dementia Rating-
CDR 0; n = 70) and 98.8% with mild cognitive impairment (CDR 0.5; n = 81) fell in the abnor-
mal biomarker categories by the A/T/N classification.
Conclusions
A large proportion of older hip fracture patients have CSF evidence of AD pathology. Preop-
erative determination of AD biomarkers may play a crucial role in identifying persons without
dementia who have underlying AD pathology in perioperative settings.
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Introduction
Alzheimer’s disease (AD) is the most common cause of dementia in the United States (U.S.),
with an estimated 5.5 million affected individuals in 2017. The annual incidence of AD is
expected to double by 2050, because of the increased number of older adults [1]. A further
indicator of the significant public health impact of AD and related dementias is the annual eco-
nomic cost estimated at upwards of 215 billion dollars in the U.S. [2].
Physical disability, with associated falls, is a significant contributor to AD related health
care costs [1]. One of the consequences of falls is hip fracture, with up to 97% of hip fractures
occurring as the result of a fall [3]. As with AD the number of hip fractures in adults 65 years
and older is increasing in the U.S., and is expected to approach 300,000/year by 2030 in the U.
S [4]. Hip fracture is associated with a multitude of complications including prolonged rehabil-
itation, loss of independence, and one-year mortality of 26% [5]. The economic cost associated
with hip fracture is also high, with annual Medicare expenditures of 2.9 billion dollars [6].
One of the major risk factors for both falls and hip fractures is gait disorder [3]. In the past
several years, much new evidence has accumulated elucidating the association between AD
pathology and gait disorders in persons without dementia. In one study, the presence of AD
pathology at autopsy was associated with more rapid rate of decline in walking speed several
years prior to death, independent of dementia [7]. More recently, amyloid-beta (Aβ) burden
measured by positron emission tomography (PET) has linked Aβ pathology with worse perfor-
mance on multiple gait parameters, in cross-sectional and longitudinal studies of older adults
with normal cognition or mild cognitive impairment (MCI) [8–10]. A prospective study of
cognitively normal older adults has also reported that imaging and CSF biomarkers suggestive
of underlying AD pathology were associated with faster time to first fall [11].
The exact mechanisms by which AD pathology is associated with gait disorders remain
unclear. However, one study demonstrated an association between gait disorder and Aβ bur-
den in striatum, especially the posterior putamen which receives its primary input from motor
and sensorimotor cortices [8]. More recently, a study examining sensorimotor integration in
AD patients with motor disturbance suggested a link with Aβ pathology and the cholinergic
system, which is a major contributor of motor function [12].
Despite the mounting evidence above, few studies have examined the prevalence of AD
pathology in hip fracture patients who arguably suffer one of the most serious complications
of gait disorders. The goal of this study was to examine a cohort of hip fracture patients for
underlying AD pathology as evidenced by CSF biomarkers, and to determine how often such
pathology is seen in hip fracture patients without dementia.
Materials and methods
Participants
The study comprised 168 consecutive hip fracture patients enrolled in the randomized clinical
trial “A Strategy to Reduce the Incidence of Postoperative Delirium in Elderly Patients”
(STRIDE) who had preoperative Clinical Dementia Rating (CDR) assessments completed
[13]. Detailed study description has been published [13,14]. Briefly, inclusion criteria were age
�65, preoperative Mini-Mental State Exam (MMSE) score�15, and eligible for spinal anes-
thesia. Main exclusion criteria were preoperative delirium, stage IV congestive heart failure, or
severe chronic obstructive pulmonary disease. Informed consent was obtained from patients,
or their appropriate legal representatives for patients unable to give informed consent due to
cognitive impairment. The Johns Hopkins Medical Institution’s Institutional Review Board
oversaw the trial.
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Study procedures
Demographic data were collected from patients, informants, and medical records. Prior to sur-
gery, trained research staff obtained history from the patients and their informants. The
research staff also administered the MMSE to the patients and the Short Form of the Infor-
mant Questionnaire on Cognitive Decline in the Elderly (Short IQCODE) to the family or
caregivers [15]. A consensus panel of two psychiatrists and one geriatrician blinded to the
intervention scored the CDR, which is a modification of the previously published CDR [16].
The CDR scoring was based on assessment of all available clinical and cognitive data, as well as
the Short IQCODE [15] and other history collected from the patient and the informant prior
to surgery.
CSF samples were collected at the onset of the routine spinal anesthesia, aliquoted and
stored at –80 oC. Previously unthawed CSF samples were analyzed for Aβ40 and Aβ42, phos-
phorylated tau (p-tau), and total tau (t-tau) at the Clinical Neurochemistry Laboratory of the
Sahlgrenska University Hospital, Mo¨lndal, Sweden. Aβ40 and Aβ42 was assayed using MSD
electrochemiluminescence assay (Meso Scale Discovery, Rockville, MD, USA), and p-tau and
t-tau were assayed using INNOTEST enzyme-linked immunosorbent assays (Fujirebio,
Ghent, Belgium) according to the manufacturer’s specifications. Assays were run with stan-
dardized internal controls to account for inter-assay variability by board-certified laboratory
technicians who were blinded to clinical data. All performed within plate approval limits from
the lab quality manger (QM) program including intra-assay coefficient of variation (CV)
below 10%. Apolipoprotein E (APOE) was genotyped at the Johns Hopkins Alzheimer’s Dis-
ease Research Center (JHADRC).
Statistics
Classification cutoff using mixture modeling was used to determine the abnormal biomarker
level of Aβ pathology as previously had been done [17,18]. The optimal cutoff ratio of CSF
Aβ42/Aβ40, which correlates well with abnormal amyloid PET [19], was determined to
be� 0.8 (CSFAβ42/40 ratio x 10) based on a population based study conducted in the same
laboratory. The biomarker of tau pathology was categorized as normal if CSF p-tau was < 60
pg/ml or abnormal if� 60 pg/ml, and biomarker of neuronal degeneration or neuronal injury
was categorized as normal if CSF t-tau was� 350 pg/ml or abnormal if> 350 pg/ml. These
cutoff values were based on previous studies that utilized similar platforms and procedures as
the current study [20] and also validated in a hip fracture population [21]. Distribution of
abnormal CSF biomarkers were described based on CDR scores.
In individuals without dementia (CDR 0 or 0.5), CSF biomarkers were further divided into
categories according to the A/T/N classification system, where “A” refers to the value of an Aβ
biomarker, “T” the value of a tau biomarker, and “N,” the value of a neurodegeneration bio-
marker [22]. In this study, CSF Aβ42/40 is classified as normal (A-) or abnormal (A+), p-tau
as normal (T-) or abnormal (T+), and t-tau as normal (N-) or abnormal (N+) based on the cut-
off values above. The A/T/N classifications were also mapped to the corresponding existing
National Institute on Aging-Alzheimer’s Association (NIA-AA) criteria as it had been previ-
ously done [23]. Distributions of these categories were described according to participants’ age
categories.
Baseline demographics were compared among different CDR groups using Χ2 or Fisher’s
exact test for dichotomous variables and one-way ANOVA F-test or Kruskal-Wallis (non-
parametric) test for continuous variables. The proportion of abnormal biomarker levels were
compared among different CDR groups using Χ2 test for dichotomous variables. P values�
0.05 were regarded as statistically significant. The required sample size was calculated based on
CSF biomarkers of hip fracture patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0204695 September 25, 2018 3 / 9
the hypothesized intervention effect (light vs. heavy anesthesia sedation) of the parent study
“A Strategy to Reduce the Incidence of Postoperative Delirium in Elderly Patients” (STRIDE)
[13]. Therefore, we evaluated the minimal detectable effect size for the between group differ-
ences of mean biomarker levels across the CDR groups based on the predetermined CDR
group sizes from the STRIDE trial. The minimal detectable effect size for the between group
differences of mean biomarker levels across the CDR groups was 0.24 using an ANOVA F-test
with CDR subgroup sizes of 70, 81, and 17, respectively, alpha level of 0.05, and power of 0.80.
Analyses were conducted using STATA 14.2 (StataCorp, College Station, TX) and GraphPad
Prism 7.00 (La Jolla, California USA).
Results
Mean patient age was 81.9 (SD 7.8), with the largest group in the� 85 year old group. About
three quarters of the patients were white females. The majority of patients were either cogni-
tively normal (CDR 0) or had mild cognitive impairment (MCI) (CDR 0.5) (Table 1). There
was a significant difference in CSF t-tau levels between the three CDR groups (p = 0.01), but
not in CSF Aβ42 (p = 0.39) or p-tau (p = 0.10) levels. All biomarker ratios including Aβ42/40,
Aβ42/p-tau, and Aβ42/t-tau differed significantly across CDR groups. APOE genotyping
showed that 24% of the patients had at least one copy of APOE-ε4. The largest proportion of
APOE-ε4 carriers was in the CDR� 1 group (Table 2).
When CSF biomarker levels were dichotomized into normal vs. abnormal based on afore-
mentioned cutoffs, close to 86% of the entire cohort had abnormal Aβ levels as represented by
Aβ42/40 ratios (Fig 1). The proportion of patients with abnormal levels of p-tau and t-tau in
the entire cohort were 37% and 65% respectively. The proportion of patients with abnormal
CSF p-tau and t-tau increased with higher (worse) CDR scores (Fig 1).
In order to examine the underlying CSF biomarker profiles of hip fracture patients without
dementia, biomarkers of patients in the CDR 0 and 0.5 groups were categorized further
according to the combination of the A/T/N and corresponding NIA-AA classification system
[23]. Among the individuals in the CDR 0 group, 88.6% (62/70) had abnormal CSF biomarker
levels. The vast majority had biomarkers suggestive of preclinical AD, and with the remainder
in the Suspected Non-Alzheimer’s Pathology (SNAP) category. In the CDR 0.5 group, 98.8%
(80/81) had abnormal biomarker levels. Most patients had biomarkers suggestive of prodromal
Table 1. Baseline clinical data by Clinical Dementia Rating (CDR) categories.
Clinical Dementia Rating (CDR)
Total 0 0.5 �1a P-value
(n = 168) (n = 70) (n = 81) (n = 17)
Demographics
Age, yrs, mean (SD) 81.9(7.75) 78.5(7.02) 84.1(6.99) 85.8(8.85) <0.001
Sex, male, n (%) 44(26) 15(21) 21(26) 8(47) 0.10
female, n (%) 124(74) 55(79) 60(74) 9(53)
Race, n (%)
Nonwhite race or Hispanic 6(3.6) 2 (2.9) 3(3.7) 1(5.9) 0.70
Educationb, n (%) 44(26) 24(34) 18(22) 2(12) 0.09
MMSE, mean (SD) 24.3(3.75) 26.6(2.55) 23.5(3.06) 19.0(4.02) <0.001
Abbreviations: Years (yrs); Mini-Mental State Examination (MMSE).
a CDR� 1 included CDR 1 (n = 13) and CDR 2 (n = 4).
b� college—attended some years of college or above.
https://doi.org/10.1371/journal.pone.0204695.t001
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AD, and the remainder were in the MCI-SNAP group (Table 3). All of the individuals (17/17)
in the CDR� 1 group had abnormal biomarker levels.
Discussion
In this study of older individuals who present with hip fracture requiring surgery, we found a
high prevalence of AD pathology evidenced by abnormal levels of CSF biomarkers overall and
in those without dementia. Although high prevalence of AD pathology is associated with older
age, this finding was also evident in younger hip fracture patients. For example, in our study,
68% of the 65–74 year old cognitively normal (CDR 0) individuals had abnormal Aβ biomarker
levels. This is a much higher rate than in the general population, such as rates of 23–32% for
abnormal amyloid levels by amyloid-PET or CSF Aβ 42 assays in similarly aged cognitively nor-
mal individuals from a recent meta-analysis [24]. Similarly, in a different population based
study that categorized cognitively normal individuals by the A/T/N system, the most prevalent
group was the normal (A-/T-/N-) biomarker category among individuals between the ages of
50 to late 70’s. In this population, the estimated prevalence of the normal (A-/T-/N-) biomarker
category at age 65 was 56% [22]. In contrast, the most prevalent group among cognitively nor-
mal 65–74 year olds in our hip fracture study was the preclinical AD category in which abnor-
mal Aβ biomarker levels were accompanied by abnormal levels of either or both p-tau and
t-tau. Only 16% in this group had normal (A-/T-/N-) biomarker profile in our study. Taken
together, our findings suggest that biomarker evidence of underlying AD or other neurodegen-
erative pathology is highly prevalent in hip fracture population across all age groups.
The strengths of this study include examination of AD biomarker profile in one of the larg-
est cohorts of well characterized hip fracture patients with CSF collection. In addition, CDR
determination in a semi-urgent surgical population provides assessment of global cognitive
Table 2. Baseline CSF data by Clinical Dementia Rating (CDR) categories.
Clinical Dementia Rating (CDR)
Total 0 0.5 � 1 p-value
(n = 168) (n = 70) (n = 81) (n = 17)
Laboratory Values
CSF, mean (SD)
Aβ 42 (pg/ml) 297.16(161.20) 316.57(151.07) 285.99(165.19) 270.46(182.5 7) 0.39
Aβ 40 (pg.ml) 5032.94(1799.75) 5049.14(1802.80) 5021.73(1765.64) 5019.68(2050.03) 0.99
Aβ 42/40a 0.59(0.20) 0.63(0.19) 0.56(0.19) 0.52(0.22) 0.03
p-tau (pg/ml)b 56.62(25.35) 51.75(20.93) 59.42(28.52) 63.00(23.51) 0.10
t-tau (pg/ml) 493.21(282.33) 419.78(195.70) 535.48(336.88) 594.20(236.42) 0.01
Aβ42/t-tau 0.71(0.38) 0.84(0.37) 0.65(0.35) 0.50(0.36) <0.001
Aβ42/p-tau 5.75(2.81) 6.59(2.72) 5.28(2.65) 4.53(3.11) 0.003
Total
APOEc (n = 158) (n = 67) (n = 76) (n = 15) p-value
APOE-ε4d, n (%) 38(24.1) 16(23.9) 16(21.1) 6(40.0) 0.29
Cerebrospinal fluid (CSF); Amyloid-beta (Aβ); total tau (t-tau); phosphorylated tau (p-tau).
aThe Aβ42/Aβ40 ratio was calculated as Aβ42/Aβ40 x 10 as previously has been done [20].
bOne subject in the CDR 0 group had p-tau below the detection limit.
cAPOE genotyping was available in 158 subjects.
dAPOE-ε4 denotes those who had at least one copy of APOE-ε4 (APOE-ε4+/ APOE-ε4+) or (APOE-ε4+/ APOE-ε4-). Percentage (%) is calculated as number of
individuals with at least one copy of APOE-ε4/subgroup total. Ninety six percent (23/24) of the patients with at least one copy of APOE-ε4 had abnormal Aβ biomarker
levels by Aβ 42/40 ratios.
https://doi.org/10.1371/journal.pone.0204695.t002
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function in addition to brief preoperative cognitive screening that is usually done in this popula-
tion. However, important limitations should be acknowledged. One limitation is that some
patients on oral anticoagulants were excluded for safety reasons. This excluded many individuals
with conditions requiring anticoagulation (e.g. atrial fibrillation), and may have excluded
patients whose cognitive impairments were largely due to vascular causes. In addition, due to
the semi-urgent nature of the hip fracture repair surgery, it was not possible to use brain imaging
(e.g. MRI) to evaluate for vascular disease burden in this study, which is also thought to contrib-
ute to gait disorders [25]. We also determined the cutoff for abnormal biomarkers based on pop-
ulation based data as well as previously published cutoffs. We acknowledge that the prevalence
of abnormal biomarkers may vary depending on different laboratory assays and different popu-
lations, and therefore our findings need to be interpreted with caution. Finally, although we
incorporated preoperative assessment of the patient in determining the CDR, it was largely
informant based and not the formal process specified in the literature [16]. However, formal pre-
operative CDR determination is most likely not feasible in a traumatic hip fracture population.
Recently, a large population based study demonstrated that individuals with AD had signifi-
cantly higher incidence of hip fracture compared to those without AD even after adjusting for
age and sex [26]. One of the most important findings from our study is that a large proportion
of individuals with hip fracture may have preclinical or prodromal AD. Therefore, higher hip
fracture risk may not be limited to only those in the Alzheimer’s dementia stage, but may also
Fig 1. High proportion of individuals with CSF biomarkers in the abnormal range in hip fracture population.
Proportion of individuals with biomarkers in the abnormal range for the entire cohort (total) and by CDR categories.
CDR 0 (n = 70), CDR 0.5 (n = 81), CDR� 1 (n = 17) CSF Aβ42/40 ratio (cutoff� 0.8): Total– 85.7% (144/168); CDR
0–80% (56/70); CDR 0.5–90.1% (73/81); CDR� 1–88.2% (15/17), (Χ2 = 3.24, df = 2, p = 0.20). CSF P-tau (cutoff� 60
pg/ml): Total– 37.1% (62/167); CDR 0–31.9% (22/69); CDR 0.5–38.3% (31/81); CDR� 1–52.9% (9/17), (Χ2 = 2.68,
df = 2, p = 0.26); One subject in the CDR 0 group had p-tau below the detection limit. CSF T-tau (cutoff>350 pg/ml):
Total– 65.5% (110/168); CDR 0–58.6% (41/70); CDR 0.5–69.1% (56/81); CDR� 1–76.5% (13/17), (Χ2 = 2.87, df = 2,
p = 0.24).
https://doi.org/10.1371/journal.pone.0204695.g001
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extend to those who are in the earlier stages. One of the reasons for the higher hip fracture risk
in AD may be the aforementioned association of AD pathology with gait disorders leading to
hip fracture. However, another reason for the higher risk of hip fracture in AD may be the role
of AD in accelerated bone loss [27]. There is mounting evidence that the brain plays an impor-
tant role in regulating bone mass, with one of the pathways thought to be the actions of the
hypothalamus including the leptinergic-sympathetic axis [28] One study showed that total
hypothalamic volume in individuals with AD was associated with bone mineral density
(BMD) after adjusting for age and sex [27]. Examination of hip fracture incidence in a larger
population based biomarker study may be able to further elucidate the association between
AD and hip fracture, and possibly determine if screening for fall risk in preclinical and/or pro-
dromal AD stage may reduce the incidence of hip fracture.
In addition, underlying AD pathology may also have continued repercussions even after
the hip fracture is repaired. Perhaps the highly prevalent perioperative cognitive changes that
hip fracture patients experience including postoperative delirium and subsequent prolonged
rehabilitation, loss of independence, and mortality may be due to brain vulnerability as sig-
naled by underlying AD pathology as well. Future direction will be to examine these outcomes
in the context of the CSF biomarker findings. In the future, biomarkers may play a crucial role
in preoperatively identifying individuals with preclinical and prodromal AD, and lead to more
targeted perioperative interventions to reduce adverse outcomes of hip fracture.
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Table 3. A/T/Na Classification for CSF biomarkers in non-demented patients with hip fracture.
CDR 0 Normalb Preclinical AD SNAP
n = 70 Stage 1 Stage 2/3
(A-/T-/N-) (A+/T-/N-) (A+/T+/N-; (A-/T+/N-;
A+/T-/N+ A-/T-/N+;
A+/T+/N+) A-/T+/N+)
Age group (yrs) % (n/subgroup total)
65–74, n = 25 16.0(4/25) 24.0(6/25) 44.0(11/25) 16.0(4/25)
75–84, n = 27 11.1(3/27) 29.6(8/27) 59.3(16/27) 0.0(0/27)
85–102, n = 18 5.6(1/18) 38.9(7/18) 44.4(8/18) 11.1(2/18)
CDR 0.5 MCI MCI MCI-SNAP
n = 81
(unlikely due to AD) (A+/T-/N-; A+/T+/N-; A+/T-/N+; (A-/T+/N-; A-/T-/N+;
(A-/T-/N-) A+/T+/N+) A-/T+/N+)
Age group (yrs) % (n/subgroup total)
65–74, n = 11 0.0(0/11) 72.7(8/11) 27.3(3/11)
75–84, n = 30 3.3(1/30) 93.3(28/30) 3.3(1/30)
85–102, n = 40 0.0(0/40) 92.5(37/40) 7.5(3/40)
Abbreviations: AD, Alzheimer’s disease; CDR, Clinical Dementia Rating; MCI, Mild Cognitive Impairment; SNAP, Suspected Non-Alzheimer Pathophysiology.
aA/T/N system used in this study: A–biomarker of fibrillary Aβ deposition (CSF Aβ42/40 ratio, < 0.08) The Aβ42/Aβ40 ratio was calculated as Aβ42/Aβ40 x 10 as
previously has been done [20]; T–biomarker of tau pathology [neurofibrillary tangles] (CSF phosphorylated tau, > 350 pg/ml); N–biomarker of AD-like
neurodegeneration or neuronal injury (CSF total tau,� 60 pg/ml).
b A/T/N system mapping to the existing NIA-AA criteria [23].
https://doi.org/10.1371/journal.pone.0204695.t003
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